Insider Selling: Aduro Biotech, Inc. (ADRO) COO Sells $314,119.87 in Stock
Aduro Biotech, Inc. (NASDAQ:ADRO) COO Gregory W. Schafer sold 25,811 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $12.17, for a total transaction of $314,119.87. Following the completion of the sale, the chief operating officer now directly owns 133,879 shares of the company’s stock, valued at $1,629,307.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Aduro Biotech, Inc. (NASDAQ ADRO) opened at 11.35 on Friday. The firm has a 50-day moving average of $12.44 and a 200 day moving average of $10.98. Aduro Biotech, Inc. has a 1-year low of $8.75 and a 1-year high of $16.15. The company’s market capitalization is $846.85 million.
Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The business had revenue of $5.90 million for the quarter, compared to the consensus estimate of $3.98 million. During the same quarter last year, the business earned $0.03 EPS. Aduro Biotech’s revenue for the quarter was down 84.9% compared to the same quarter last year. On average, analysts anticipate that Aduro Biotech, Inc. will post ($1.37) EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. acquired a new position in Aduro Biotech during the fourth quarter valued at approximately $324,000. State Street Corp raised its position in Aduro Biotech by 1.3% in the fourth quarter. State Street Corp now owns 573,804 shares of the biotechnology company’s stock valued at $6,544,000 after buying an additional 7,597 shares during the period. Renaissance Technologies LLC acquired a new position in Aduro Biotech during the fourth quarter valued at approximately $241,000. Norges Bank acquired a new position in Aduro Biotech during the fourth quarter valued at approximately $3,266,000. Finally, Teachers Advisors LLC raised its position in Aduro Biotech by 8.3% in the fourth quarter. Teachers Advisors LLC now owns 60,317 shares of the biotechnology company’s stock valued at $688,000 after buying an additional 4,625 shares during the period. Institutional investors and hedge funds own 35.60% of the company’s stock.
ADRO has been the subject of several recent research reports. BidaskClub raised shares of Aduro Biotech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. HC Wainwright initiated coverage on shares of Aduro Biotech in a research note on Monday, May 1st. They issued a “buy” rating and a $18.00 price target for the company. Rodman & Renshaw initiated coverage on shares of Aduro Biotech in a research note on Monday, May 1st. They issued a “buy” rating and a $18.00 price target for the company. Zacks Investment Research raised shares of Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Tuesday, July 4th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $30.00 price target on shares of Aduro Biotech in a research note on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. Aduro Biotech presently has an average rating of “Buy” and an average price target of $19.00.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.